Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

Titan America's initial public offering was priced toward the low end of expectations, giving the U.S. arm of Belgian cement producer Titan Cement International an initial market value of about $2.95 billion.

Clinical-stage biopharmaceutical company Aardvark Therapeutics (AARD) priced its IPO of ~5.89M shares at $16.00 per share. All of the shares are being offered by Aardvark. The California-based startup plans to use proceeds to support the development of hunger-suppressing drugs for the rare disease Prader-Willi syndrome and obesity-related